News articles about Aldeyra Therapeutics (NASDAQ:ALDX) have been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aldeyra Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.2133390722988 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Aldeyra Therapeutics (ALDX) opened at $7.25 on Friday. The firm has a market cap of $138.61, a price-to-earnings ratio of -5.18 and a beta of 0.59. Aldeyra Therapeutics has a twelve month low of $3.80 and a twelve month high of $11.90. The company has a current ratio of 20.35, a quick ratio of 20.35 and a debt-to-equity ratio of 0.02.
Several research firms recently issued reports on ALDX. ValuEngine raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Seaport Global Securities began coverage on shares of Aldeyra Therapeutics in a report on Friday, January 26th. They set a “buy” rating and a $13.00 target price on the stock. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a report on Tuesday, January 2nd. Finally, Cantor Fitzgerald began coverage on shares of Aldeyra Therapeutics in a report on Tuesday, October 24th. They set an “overweight” rating and a $22.00 target price on the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $16.79.
TRADEMARK VIOLATION NOTICE: “Aldeyra Therapeutics (ALDX) Earns Daily Media Impact Rating of 0.13” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/18/aldeyra-therapeutics-aldx-earns-daily-media-impact-rating-of-0-13.html.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.